Veracyte, Inc. (VCYT)

NASDAQ: VCYT · USD

$50.4

+0.07 (+0.1%)· Recorded snapshot

Market cap	4B
Revenue (ttm)	561.9M
Net income (ttm)	114.5M
EPS (ttm)	$1.39
Shares out	80.4M
P/E (trailing)	36.1x
P/E (forward)	28.2x
Volume	1,074,347
Beta	1.95

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 561.9M
Net income (ttm): 114.5M
EPS (ttm): $1.39
P/E (trailing): 36.1x
P/E (forward): 28.2x
Market cap: 4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E28.2

P25 n/aP50 n/aP75 n/a

Trailing P/E36.1

P25 n/aP50 n/aP75 n/a

ROE8.8

P25 n/aP50 n/aP75 n/a

ROIC9.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All VCYT indicators

Market & fundamental data

Available fields

254

Groups with data

Currency

USD

Showing 254 of 254 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001384101
Company name	Veracyte, Inc.
Country	United States
Country code	US
CUSIP number	92337F107
Earnings date	2026-11-04
Earnings time	amc
Employees	755
Employees change	-69
Employees growth	-8.37%
Enterprise value	$3.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2006
In index	RUSSELL2000
Industry	Diagnostics & Research
IPO date	2013-10-30
Is primary listing	Yes
Is SPAC	No
ISIN number	US92337F1075
Last 10-K release date	2026-02-26
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$4B
Market cap category	Mid-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$50.35
Price currency	USD
Sector	Healthcare
SIC code	8071
Stock price date	2026-10-28
Symbol	VCYT
U.S. state	California
Website	https://www.veracyte.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	23.98x
Earnings yield	2.77%
EV/Earnings	31.37x
EV/EBIT	38.75x
EV/EBITDA	31.64x
EV/FCF	21.64x
EV/Sales	6.39x
FCF / EV yield	4.62%
FCF yield	4.11%
Forward EV/Sales	5.79x
Forward P/E	28.17x
Forward P/S	6.5x
Graham number	23.28105
Graham upside	-53.63%
Industry forward P/E	30.87x
Industry P/E	50.24x
P/(FCF - SBC) ratio	34.36x
P/(OCF - SBC) ratio	31.08x
P/B ratio	2.91x
P/E ratio	36.11x
P/FCF ratio	24.32x
P/OCF ratio	22.63x
P/S ratio	7.18x
Price / tangible book value	7.49x
Price/EBITDA ratio	35.56x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	16.49%
EBITDA margin	20.2%
Effective tax rate	1.32%
FCF margin	29.54%
Gross margin	73.76%
Operating margin	16.49%
Pretax margin	20.65%
Profit margin	20.37%
Profit per employee	$151,633
Profitable quarters	4
Profitable years	2
Revenue per employee	$744,238
ROA	4.09%
ROA (5Y)	-1.08%
ROCE	6.51%
ROE	8.77%
ROE (5Y)	-2.57%
ROIC	9.69%
ROIC (5Y)	-2.74%
SBC / revenue	8.63%
Tax / revenue	0.27%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	315.37%
EPS growth (QoQ)	-11.43%
EPS growth quarters	4
EPS growth years	2
FCF growth	97.69%
FCF growth (Q)	32.95%
FCF growth (QoQ)	33.22%
FCF growth 3Y	93.19%
Gross profit growth	22.57%
Gross profit growth (Q)	19.81%
Gross profit growth 3Y	23.53%
Gross profit growth 5Y	31.34%
Net income growth	334.72%
Net income growth (QoQ)	-11.21%
Net income growth quarters	4
Net income growth years	2
OCF growth	90.88%
OCF growth (Q)	36.37%
OCF growth (QoQ)	30.13%
OCF growth 3Y	78.68%
Operating income growth	159.64%
Operating income growth (Q)	50.82%
Revenue growth	17.28%
Revenue growth (Q)	15.49%
Revenue growth (QoQ)	8.09%
Revenue growth 10Y	26.25%
Revenue growth 3Y	19.58%
Revenue growth 5Y	28.97%
Revenue growth quarters	24
Revenue growth years	5

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-12.4M
Depreciation and amortization	$20.8M
EBIT	$92.7M
EBITDA	$113.5M
EPS	$1.39
FCF per share	$2.06
Financing cash flow	$338,000
Free cash flow	$166M
Free cash flow minus SBC	$117.5M
Gross profit	$414.4M
Income taxes	$1.5M
Investing cash flow	$-98.7M
Net cash flow	$80M
Net income	$114.5M
Operating cash flow minus SBC	$129.9M
Operating income	$92.7M
Revenue	$561.9M
Stock-based compensation	$48.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	18.6
Book value per share	$17.28
Debt / EBITDA	0.3
Debt / equity	0.03
Debt / FCF	0.24
Goodwill	$767.2M
Long-term assets	$911.6M
Long-term liabilities	$35.2M
Net cash (debt)	$445.1M
Net cash / market cap	11.03%
Net cash growth	64.82%
Net debt / EBITDA	-3.92
Net debt / equity	-0.32
Net debt / FCF	-2.68
Piotroski F-Score	7
Property, plant and equipment	$57.1M
Shareholders' equity	$1.4B
Tangible book value	$538.5M
Tangible book value per share	$6.70
Total assets	$1.5B
Total cash	$485.2M
Total debt	$40.1M
Total liabilities	$98M
WACC	14.81%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.4
Current assets	$574.8M
Current liabilities	$62.7M
Current ratio	9.16
Inventory turnover	6.19
Net working capital	$32.6M
Quick ratio	8.6
Working capital	$512M
Working capital turnover	1.32

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.11%
Dividend yield	0%
Shareholder yield	-2.11%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	547.17%
10Y return CAGR	20.54%
10Y total return	547.17%
150-day SMA	$44.81
1D price change	0.14%
1M price change	10.83%
1M total return	10.83%
1W price change	8.94%
1W total return	8.94%
1Y price change	39.98%
1Y return CAGR	40.01%
1Y total return	39.98%
20-day SMA	$45.50
200-day SMA	$42.74
3M price change	-9.46%
3M total return	-9.46%
3Y price change	155.33%
3Y return CAGR	36.67%
3Y total return	155.33%
50-day SMA	$44.06
50-day SMA vs 200-day SMA	50over200
52-week high	$60.91
52-week high date	2026-06-30
52-week low	$29.46
52-week low date	2026-03-27
5Y price change	10.98%
5Y return CAGR	2.11%
5Y total return	10.98%
6M price change	48.74%
6M total return	48.74%
All-time high	$86.03
All-time high date	2021-02-10
All-time low	$4.21
All-time low date	2016-03-24
Average true range (ATR)	$2.39
Average volume	1.2M
Beta (1Y)	0.59
Beta (2Y)	0.95
Beta (5Y)	1.95
Change from 52-week high	-17.34%
Change from 52-week low	70.94%
Change from all-time high	-41.47%
Change from all-time low	1,095.96%
Change from open	-2.1%
Day's gap	2.29%
Dollar volume	$54.1M
High price	$51.43
Low price	$49.78
Monthly RSI	58.9
Open price	$51.43
Position in 52-week range	34.55%
Premarket change	1.05%
Premarket close	$50.28
Premarket price	$50.81
Premarket volume	1.8K
Previous close	$50.28
Price vs 150-day SMA	12.38%
Price vs 20-day SMA	10.65%
Price vs 200-day SMA	17.81%
Price vs 50-day SMA	14.28%
Relative volume	0.92
RSI	65.65
Sharpe ratio	0.77
Sharpe ratio (3Y)	0.72
Sharpe ratio (5Y)	0.28
Sortino ratio	1.4
Sortino ratio (3Y)	1.31
Sortino ratio (5Y)	0.53
Volume	1.1M
Weekly RSI	58.46
YTD price change	19.6%
YTD total return	19.6%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	79.9M
Float percentage	99.37%
Shares change (QoQ)	0.92%
Shares change (YoY)	2.11%
Shares held by insiders	0.59%
Shares held by institutions	113.87%
Shares outstanding	80.4M
Short % of float	12.74%
Short % of shares	12.66%
Short ratio	7.1 days

Deeper analysis on VCYT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this VCYT report

Is a complete VCYT research report available?

No complete published report is available for Veracyte, Inc. (VCYT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Veracyte, Inc. (VCYT)

Price

Financial snapshot

Fair-value bridge

Latest news · VCYT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All VCYT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VCYT

Frequently asked questions